May 2, 2025 Q1 2025 Results Stephan B. Tanda, Aptar President and CEO Vanessa Kanu, Executive Vice President and CFO Forward Looking Statements & Non-GAAP Financial Measures This presentation includes forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on management's beliefs and assumptions in light of information currently available to managem ...

Exhibit 99.1 Crystal Lake, Illinois, May 1, 2025 -- AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today reported the following first quarter results for the period ended March 31, 2025, as compared to the corresponding period of the last fiscal year. First Quarter 2025 Highlights (compared to the prior year quarter) "Our pharma and closures segments delivered solid results with increased product sales in the quarter. We saw growing ...

PRINCETON, N.J., May 1, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in blood purification therapies for life-threatening conditions in the intensive care unit and cardiac surgery, today provided a regulatory update for DrugSorb™-ATR, its FDA-designated Breakthrough Device.  DrugSorb-ATR is designed to reduce the severity of bleeding in patients undergoing coronary artery bypass grafting (CABG) surgery within 2 days of stopping the antiplatelet drug Brilinta® (ticagrelor, AstraZene ...

Wall Street expects a year-over-year decline in earnings on lower revenues when AptarGroup (ATR) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on May 1. On the oth ...

Group 1 - AptarGroup, Inc. is expected to benefit from growth in its Pharma and Closure segments, while facing challenges in the Beauty segment in the upcoming quarters [1] - The company focuses on GARP (Growth at Reasonable Price) opportunities within the industrial, consumer, and technology sectors [1]

Core Viewpoint - Technip Energies has secured a significant contract for the Blue Point Number One ATR Project, which aims to establish the world's largest low-carbon ammonia plant with a capacity of approximately 1.4 million metric tons per year [1][3]. Group 1: Project Details - The Blue Point Number One ATR Project is a collaboration between CF Industries, JERA, and MITSUI & CO, focusing on low-carbon ammonia production [1]. - Technip Energies will handle engineering, procurement, equipment, and module fabrication, utilizing its expertise in modularization and project delivery [2]. - The project is expected to achieve over 95% CO2 recovery, marking a significant advancement for the ammonia industry [3]. Group 2: Technological Integration - Technip Energies will integrate Topsoe's SynCOR AmmoniaTM technology into the project, showcasing its capability to incorporate advanced technologies into large-scale industrial projects [2][3]. - The low-carbon ammonia produced will cater to anticipated strong global demand for various applications, including energy and marine fuels [3]. Group 3: Company Insights - Arnaud Pieton, CEO of Technip Energies, emphasized the company's role in delivering large-scale facilities that incorporate state-of-the-art technologies, contributing to global decarbonization efforts [4]. - Technip Energies is recognized as a global technology and engineering leader, with a revenue of €6.9 billion in 2024, focusing on critical markets such as energy and decarbonization [5][6].

Core Viewpoint - AptarGroup, Inc. reported strong fourth-quarter 2024 adjusted earnings per share (EPS) of $1.52, exceeding expectations and reflecting a 27% year-over-year increase from $1.20 per share [1][2] Financial Performance - Total revenues for Q4 2024 increased by 1.1% year over year to $848 million, but fell short of the Zacks Consensus Estimate of $858 million [3] - Adjusted operating income rose 10.8% year over year to $127.5 million, with an adjusted operating margin of 15%, up from 13.7% in the prior year [4] - Adjusted EBITDA increased by 8.6% year over year to $194.9 million, with an adjusted EBITDA margin of 23% compared to 21.4% in Q4 2023 [5] Segment Performance - Pharma segment revenues grew by 4.1% year over year to $400.7 million, although it missed the estimate of $412 million [6] - Beauty segment revenues decreased by 4.8% year over year to $274 million, impacted by lower tooling sales [8] - Closures segment revenues rose by 4.6% year over year to $173 million, with core sales increasing by 7% [10] Cash Position and Shareholder Returns - As of December 31, 2024, cash and cash equivalents stood at $223.8 million, with cash flow from operations reaching $643 million for the year [12] - The board authorized a $500 million common stock repurchase and declared a quarterly cash dividend of 45 cents per share [12][13] Annual Performance - For the full year 2024, adjusted EPS increased by 17.7% year over year to $5.65, surpassing the Zacks Consensus Estimate of $5.38 [14] - Total revenues for 2024 rose by 2.7% year over year to $3.58 billion, missing the consensus estimate of $3.6 billion [14] Outlook - The company anticipates first-quarter 2025 adjusted EPS to be in the range of $1.11-$1.19 [15] Stock Performance - ATR shares have gained 4% over the past year, compared to the industry's growth of 9.5% [16]

Core Insights - AptarGroup's international revenue performance is crucial for assessing its financial resilience and growth prospects [1][2][3] Revenue Performance - The total revenue for AptarGroup in the quarter was $848.09 million, reflecting a year-over-year increase of 1.2% [4] - Latin America generated $67.16 million, accounting for 7.92% of total revenue, which was a decrease of 2.25% from the projected $68.71 million [5] - Asia contributed $94.51 million, representing 11.14% of total revenue, exceeding the consensus estimate of $89.99 million by 5.02% [6] Future Revenue Forecasts - Analysts project AptarGroup's total revenue for the current fiscal quarter to be $920.38 million, indicating a 0.5% increase from the previous year [7] - For the full year, total annual revenue is expected to reach $3.76 billion, marking a 5% increase compared to last year, with Latin America and Asia projected to contribute 8% ($300.62 million) and 10.3% ($385.55 million) respectively [8] Market Dynamics - The reliance on international markets presents both opportunities and challenges for AptarGroup, making it essential to monitor international revenue trends for future projections [9] - Analysts closely observe these trends, especially in light of global interdependence and geopolitical issues, which can influence earnings forecasts [10] Stock Performance - Over the past month, AptarGroup's stock has declined by 6.7%, while the Zacks S&P 500 composite increased by 2.1% [13] - In the last three months, the company's stock price has decreased by 14%, contrasting with a 1.2% rise in the S&P 500 index [13]

Financial Data and Key Metrics Changes - AptarGroup, Inc. achieved core sales growth of 2% in Q4 2024, with adjusted earnings per share of $1.52, exceeding guidance due to better operational performance and a lower effective tax rate [7][32] - The adjusted EBITDA margin for Q4 was at 23%, up from 21.4% in the prior year, driven by productivity gains and cost mitigation measures [8][32] - For the full year, adjusted earnings per share increased by 18% to $5.64, with adjusted EBITDA margins expanding by 130 basis points to 21.6% [46][48] Business Line Data and Key Metrics Changes - The pharma segment achieved 8% core sales growth for the full year, with a 35% adjusted EBITDA margin driven by higher value products and royalties [9][10] - The beauty segment saw a 3% decline in core sales in Q4, primarily due to lower sales of prestige products, although personal care technologies grew [14][38] - The closures segment reported a 7% increase in core sales, with food sales up 9% and beverage sales up 10%, leading to an adjusted EBITDA margin of 16.1% [39][40] Market Data and Key Metrics Changes - In the beauty segment, Europe maintained its adjusted EBITDA margin, while North America showed progressive recovery, and China faced challenges but showed improvement towards the end of the year [16][17] - India experienced good growth, albeit from a low base, and new project activity is encouraging across most regions [17] - The closures segment returned to its core sales long-term target range, driven by increased global demand for food and beverage dispensing technologies [18] Company Strategy and Development Direction - The company anticipates continued strength in its proprietary drug delivery systems, particularly in the pharma segment, which is expected to be the main driver of growth [60] - AptarGroup is focusing on innovation and sustainability, with ongoing efforts to improve productivity and reduce costs across all segments [56][159] - The company plans to continue returning capital to shareholders, with expectations for an increasing dividend for the 32nd consecutive year [19][50] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism for 2025, despite anticipated challenges from foreign exchange impacts and higher tax rates [58][60] - The company expects to see gradual improvement in the beauty segment and continued growth in the pharma segment, particularly in injectables and proprietary drug delivery systems [61][62] - Management highlighted the importance of managing costs and improving operational efficiencies to support future growth [62] Other Important Information - The company returned $183 million to shareholders in 2024, including $114 million in dividends and $69 million in share repurchases, marking a 20% increase from 2023 [50] - The effective tax rate for Q4 was 13%, significantly lower than the previous year's 23%, due to the realization of deferred tax assets [33] Q&A Session Summary Question: Can you discuss the green shoots in China and their potential impact on 2025? - Management noted that local brands are gaining market share in China, and there is optimism for growth in skincare and fragrance as the market shows signs of vitality [72][75] Question: What are the expectations for earnings per share growth in 2025, excluding currency and tax effects? - Management is cautiously optimistic about achieving double-digit EPS growth in 2025, driven by cost reductions and operational efficiencies [79][80] Question: What is the impact of the recent French tax legislation on the company's financials? - The new tax legislation will impact the entire year, with an expected increase in the effective tax rate compared to 2024 [82] Question: Can you elaborate on the destocking in cold and flu products and the timeline for normalization? - Management indicated that there are signs of bottoming out in consumer healthcare, with expectations for sequential increases as the flu season progresses [102] Question: What is the outlook for the injectables segment in 2025? - Management remains bullish on the injectables segment, citing a strong pipeline and order book, but is cautious about the ramp-up timing [110] Question: How does the company view the impact of tariffs on its operations? - Management expressed that tariffs are not a significant concern, as the company primarily produces in-region for the region [122] Question: What are the long-term goals for return on invested capital (ROIC)? - Management stated that they do not frequently change long-term targets but will review ROIC goals in the upcoming September meeting [124]

During the course of this presentation, certain non-GAAP financial information will be presented. Refer to the Appendix at the end of this presentation for additional information and a reconciliation to the most directly comparable GAAP measures. However, we are not able to reconcile forward-looking non- GAAP financial measures because certain reconciling items are dependent on future events that either cannot be controlled, such as exchange rates and changes in the fair value of equity investments, or reli ...